European Heart Journal Advance Access originally published online on December 23, 2007
European Heart Journal 2008 29(4):455-461; doi:10.1093/eurheartj/ehm562
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial
1 Deutsches Herzzentrum, Technische Universität, Lazarettstrasse 36, 80636 Munich, Germany
2 Herz-Zentrum, Bad Krozingen, Germany
3 St Antonius Ziekenhuis, Nieuwegein, The Netherlands
4 Klinikum Garmisch-Partenkirchen, Germany
5 1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany
6 Geisinger Clinic, Danville, PA, USA
Received 31 July 2007; revised 26 October 2007; accepted 5 November 2007; online publish-ahead-of-print 23 December 2007.
* Corresponding author. Tel: +49 89 12184577, Fax: +49 89 12184053. Email: kastrati{at}dhm.mhn.de
See page 429 for the editorial comment on this article (doi:10.1093/eurheartj/ehm624)
Aims: The aim of this study is to investigate whether the benefit of abciximab in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACSs) undergoing percutaneous coronary intervention (PCI) after pre-treatment with 600 mg clopidogrel is sustained at 1 year.
Methods and results: We performed 1-year follow-up of 2022 high-risk patients with NSTE-ACS undergoing urgent PCI, who were randomized to abciximab or placebo after pre-treatment with 600 mg clopidogrel in the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. The combined incidence of death, myocardial infarction, or target vessel revascularization at 1 year was the primary outcome analysis. At 1 year, the primary outcome was reached in 23.3% of patients allocated to abciximab vs. 28.0% of patients allocated to placebo [relative risk (RR) 0.80, 95% confidence interval (CI) 0.67–0.95, P = 0.012]. The combined incidence of death or myocardial infarction was 11.6% in patients allocated to abciximab vs. 15.3% in patients allocated to placebo (RR 0.74, 95% CI 0.59–0.94, P = 0.015).
Conclusion: In high-risk patients with NSTE-ACS undergoing a PCI after pre-treatment with 600 mg clopidogrel, adverse events occurred less frequently with abciximab and the early benefit was maintained at 1 year after administration.
Key Words: Abciximab • Acute coronary syndrome • Clopidogrel • Percutaneous coronary intervention
Presented at the Clinical Trial Update Sessions of the Congress of the European Society of Cardiology. 1–5 September 2007, Vienna, Austria. Trial Registration ClinicalTrials.gov Identifier: NCT00133003
[ClinicalTrials.gov]
.
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Platelet glycoprotein IIb/IIIa receptor inhibitors—end of an era?
- Marco Roffi and Debabrata Mukherjee
EHJ 2008 29: 429-431.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Giugliano, J. A. White, C. Bode, P. W. Armstrong, G. Montalescot, B. S. Lewis, A. van `t Hof, L. G. Berdan, K. L. Lee, J. T. Strony, et al. Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes N. Engl. J. Med., May 21, 2009; 360(21): 2176 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Roffi and D. Mukherjee Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era? Eur. Heart J., February 2, 2008; 29(4): 429 - 431. [Full Text] [PDF]
|
|